Literature DB >> 17659055

Contribution of natural anticoagulant and fibrinolytic factors in modulating the clinical severity of haemophilia patients.

Shrimati Shetty1, Sonal Vora, Bipin Kulkarni, Leenam Mota, Manasi Vijapurkar, Leera Quadros, Kanjaksha Ghosh.   

Abstract

The role of natural anticoagulants, fibrinolytic cascade factors and common prothrombotic gene polymorphisms in modulating disease severity were studied in 35 'clinically mild' and 37 'clinically severe' haemophilia patients with severe factor VIII or IX deficiency (<0.01 IU/ml). Strong association of deficiencies of proteins C and S, antithrombin III, tissue factor pathway inhibitor and tissue plasminogen activator, together with factor V Leiden and endothelial protein C receptor 23 bp insertion polymorphisms were observed in the 'clinically milder' group as compared with the 'clinically severe' group. These results indicate a synergistic modulation of bleeding tendency in haemophilia patients by factors in the anticoagulant and fibrinolytic systems.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17659055     DOI: 10.1111/j.1365-2141.2007.06693.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  16 in total

1.  Platelet factor 4 inhibits thrombomodulin-dependent activation of thrombin-activatable fibrinolysis inhibitor (TAFI) by thrombin.

Authors:  Laurent O Mosnier
Journal:  J Biol Chem       Date:  2010-11-01       Impact factor: 5.157

2.  An RNAi therapeutic targeting antithrombin to rebalance the coagulation system and promote hemostasis in hemophilia.

Authors:  Alfica Sehgal; Scott Barros; Lacramioara Ivanciu; Brian Cooley; June Qin; Tim Racie; Julia Hettinger; Mary Carioto; Yongfeng Jiang; Josh Brodsky; Harsha Prabhala; Xuemei Zhang; Husain Attarwala; Renta Hutabarat; Don Foster; Stuart Milstein; Klaus Charisse; Satya Kuchimanchi; Martin A Maier; Lubo Nechev; Pachamuthu Kandasamy; Alexander V Kel'in; Jayaprakash K Nair; Kallanthottathil G Rajeev; Muthiah Manoharan; Rachel Meyers; Benny Sorensen; Amy R Simon; Yesim Dargaud; Claude Negrier; Rodney M Camire; Akin Akinc
Journal:  Nat Med       Date:  2015-04-13       Impact factor: 53.440

3.  Future of Haemophilia Research in India.

Authors:  Kanjaksha Ghosh; Rinku Shukla
Journal:  Indian J Hematol Blood Transfus       Date:  2017-09-04       Impact factor: 0.900

4.  Future of Haemophilia Research in India.

Authors:  Kanjaksha Ghosh; Rinku Shukla
Journal:  Indian J Hematol Blood Transfus       Date:  2017-08-21       Impact factor: 0.900

5.  Impact of Prothrombotic Risk Factors in a Cohort of Egyptian Hemophilia A Patients.

Authors:  Mona Salah El-Din Hamdy; Aml Soliman Nasr; Manal Mohamed Makhlouf; Zainab Ali El-Saadany; Magy Samir; Dalia Saber Morgan
Journal:  Mol Diagn Ther       Date:  2016-04       Impact factor: 4.074

6.  Low plasma levels of tissue factor pathway inhibitor in patients with congenital factor V deficiency.

Authors:  Connie Duckers; Paolo Simioni; Luca Spiezia; Claudia Radu; Sabrina Gavasso; Jan Rosing; Elisabetta Castoldi
Journal:  Blood       Date:  2008-08-11       Impact factor: 22.113

Review 7.  Novel treatments for hemophilia through rebalancing of the coagulation cascade.

Authors:  Yakun Zhao; Angela C Weyand; Jordan A Shavit
Journal:  Pediatr Blood Cancer       Date:  2021-02-12       Impact factor: 3.167

8.  Targeting of antithrombin in hemophilia A or B with investigational siRNA therapeutic fitusiran-Results of the phase 1 inhibitor cohort.

Authors:  K John Pasi; Toshko Lissitchkov; Vasily Mamonov; Tim Mant; Margarita Timofeeva; Catherine Bagot; Pratima Chowdary; Pencho Georgiev; Liana Gercheva-Kyuchukova; Kate Madigan; Huy Van Nguyen; Qifeng Yu; Baisong Mei; Craig C Benson; Margaret V Ragni
Journal:  J Thromb Haemost       Date:  2021-05-18       Impact factor: 5.824

9.  Coagulation disorders seen through the window of molecular biology.

Authors:  Kanjaksha Ghosh
Journal:  Indian J Hum Genet       Date:  2007-09

10.  Factor VIII prophylaxis effects outweigh other hemostasis contributors in predicting severe haemophilia A joint outcomes.

Authors:  Beth Boulden Warren; Linda Jacobson; Christine Kempton; George R Buchanan; Michael Recht; Deborah Brown; Cindy Leissinger; Amy D Shapiro; Thomas C Abshire; Marilyn J Manco-Johnson
Journal:  Haemophilia       Date:  2019-05-21       Impact factor: 4.263

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.